[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor

  1. Giacomo Carrà1,
  2. Anna Rizzi1,
  3. Remo Guerrini,
  4. Timothy A. Barnes,
  5. John McDonald,
  6. Christopher P. Hebbes,
  7. Flora Mela,
  8. Velga A. Kenigs,
  9. Giuliano Marzola,
  10. Daniela Rizzi,
  11. Elaine Gavioli,
  12. Silvia Zucchini,
  13. Domenico Regoli,
  14. Michele Morari,
  15. Severo Salvadori,
  16. David J. Rowbotham,
  17. David G. Lambert,
  18. Daniel R. Kapusta and
  19. Girolamo Calo'
  1. Department of Experimental and Clinical Medicine, Section of Pharmacology and Neuroscience Center (G.C., A.R., F.M., G.M., D.R., E.G., S.Z., D.R., M.M., G.C.) and Department of Pharmaceutical Sciences and Biotechnology Center (R.G., S.S.), University of Ferrara, Ferrara, Italy; Department of Cardiovascular Sciences, Pharmacology and Therapeutics Group (T.A.B., J.M., C.P.H., D.G.L.) and Department of Health Sciences, Division of Anaesthesia, Critical Care and Pain Management (D.J.R.), Leicester Royal Infirmary, Leicester, United Kingdom; and Department of Pharmacology (V.A.K., D.R.K.), Louisiana State University, Health Sciences Center, New Orleans, Louisiana
  1. Address correspondence to:
    Dr. Girolamo Calo', Department of Experimental and Clinical Medicine, Section of Pharmacology, via Fossato di Mortara 19, 44100 Ferrara, Italy. E-mail: g.calo{at}unife.it

Abstract

A novel ligand for the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), has been generated by combining in the N/OFQ-NH2 sequence two chemical modifications, [Arg14,Lys15] and [(pF)Phe4], that have been previously demonstrated to increase potency. In vitro, UFP-102 bound with high affinity to the human NOP receptor, showed at least 200-fold selectivity over classical opioid receptors, and mimicked N/OFQ effects in CHOhNOP cells, isolated tissues from various species, and mouse cortical synaptosomes releasing 5-hydroxytryptamine. UFP-102 showed similar maximal effects but higher potency (2- to 48-fold) relative to N/OFQ. The effects of UFP-102 were sensitive to NOP-selective antagonists J-113397 [(±)-trans-1-[1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one] (pA2 = 7.75–8.12) and UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ-NH2)(pA2 = 6.91–7.33) but not to naloxone, and no longer observed in tissues taken from NOP receptor knockout mice (NOP–/–). In vivo, UFP-102 (0.01–0.3 nmol i.c.v.) mimicked the pronociceptive action of N/OFQ (0.1–10 nmol i.c.v.) in the mouse tail withdrawal assay, displaying higher potency and longer lasting effects. The action of UFP-102 was not apparent in NOP–/– mice. Similar results were obtained measuring locomotor activity in mice. In conscious rats, UFP-102 (0.05 nmol i.c.v.) produced a marked and sustained decrease in heart rate, mean arterial pressure, and urinary sodium excretion and a profound increase in urine flow rate. These effects were comparable with those evoked by N/OFQ at 5 nmol. Collectively, these findings demonstrate that UFP-102 behaves as a highly potent and selective NOP receptor agonist that produces long-lasting effects in vivo.

Footnotes

  • This work was financially supported by the University of Ferrara (60% grant to G.C.), the Italian Ministry of the University (Grant FIRB 2001 to D.R.), by the International Association for the Study of Pain (collaborative travel grant Leicester/Ferrara), and by National Institutes of Health (collaborative Grant NHLBI HL-71212 to D.R.K. and D.R., and NIDDK DK-43337 and DK-02605 to D.R.K.).

  • doi:10.1124/jpet.104.077339.

  • ABBREVIATIONS: N/OFQ, nociceptin/orphanin FQ; NOP, nociceptin/orphanin FQ peptide receptor; J-113397, (±)-trans-1-[1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; UFP-101, [Nphe1,Arg14,Lys15]N/OFQ-NH2; UFP-102, [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2; 5-HT, 5-hydroxytryptamine; CHO, Chinese hamster ovary; KOP, κ-opioid peptide receptor; DOP, δ-opioid peptide receptor; MOP, μ-opioid peptide receptor; [35S]GTPσS, guanosine 5′-O-(3-[35S]thio)triphosphate; BSA, bovine serum albumin; ANOVA, analysis of variance; SB-612111, (–)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol; Ro 64-6198, (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one; ZP120, Ac-RYYRWK(7)-NH2.

  • ↵1 G.C. and A.R. contributed equally to this work.

    • Received September 8, 2004.
    • Accepted October 25, 2004.
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print October 27, 2004, doi: 10.1124/jpet.104.077339 JPET March 2005 vol. 312 no. 3 1114-1123
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)
  4. All Versions of this Article:
    1. jpet.104.077339v1
    2. 312/3/1114 most recent

Classifications

Responses

  1. Submit a response
  2. No responses published

Current Issue

  1. November 2009, 331 (2)
  1. Current Issue
  1. Alert me to new issues of JPET